Phase 3 clinical trial of COVAXIN shows 81 per cent efficacy: Bharat Biotech

The Indian Council of Medical Research informed on March 3, 2021, that the results of phase 3 clinical trial of COVAXIN, which ICMR has developed in partnership with Bharat Biotech, has shown an interim vaccine efficacy of 81% in preventing COVID-19.

The phase 3 clinical trial was jointly initiated by ICMR and Bharat Biotech International Limited in mid-November 2020. The trial has been conducted on a total of 25,800 individuals across 21 sites.

Leave a Reply

Your email address will not be published. Required fields are marked *